What was the patient population enrolled in the NSABP B-42 trial?
Premenopausal women with triple-negative breast cancer receiving adjuvant chemotherapy
Postmenopausal women with ER-positive breast cancer who were disease-free after 5 years of adjuvant endocrine therapy, randomized to extended letrozole or placebo
Postmenopausal women with HER2-positive disease receiving trastuzumab-based therapy